Pseudomonas aeruginosa outer membrane vesicles modulate host immune responses by targeting the toll-like receptor 4 signaling pathway

Infection and Immunity

Volumn 81, Issue 12, 2013, Pages 4509-4518

  Zhao, Kelei ^a,b   Deng, Xin ^c   He, Chuan ^c   Yue, Bisong ^b   Wu, Min ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b SICHUAN UNIVERSITY   (China)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERITORAN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 4;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL OUTER MEMBRANE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; LUNG ALVEOLUS EPITHELIUM; LUNG INFECTION; MEMBRANE VESICLE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUORUM SENSING; SIGNAL TRANSDUCTION;

ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; CELL LINE; CYTOPLASMIC VESICLES; EPITHELIAL CELLS; HUMANS; IMMUNIZATION; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPID A; LIPOPOLYSACCHARIDES; LUNG; MICE; MICE, INBRED C57BL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS VACCINES; PULMONARY ALVEOLI; RESPIRATORY MUCOSA; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; VACCINATION;

EID: 84890159252     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01008-13     Document Type: Article

References (53)

1. Mizgerd JP. 2006. Lung infection-a public health priority. PLoS Med. 3:e76. doi:10.1371/journal.pmed.0030076.
2. Lyczak JB, Cannon CL, Pier GB. 2000. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect. 2:1051-1060.
3. Boucher RC. 2004. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur. Respir. J. 23:146-158.
4. Driscoll JA, Brody SL, Kollef MH. 2007. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 67:351-368.
5. Blanke SR. 2006. Portals and pathways: principles of bacterial toxin entry into host cells. Microbe 1:26-32.
6. Bomberger JM, MacEachran DP, Coutermarsh BA, Ye S, Stanton BA. 2009. Long-distance delivery of bacterial virulence factors by Pseudomonas aeruginosa outer membrane vesicles. PLoS Pathog. 5:e1000382. doi:10.1371/journal.ppat.1000382.
7. Ernst JD. 2000. Bacterial inhibition of phagocytosis. Cell. Microbiol. 2:379-386.
8. Alba BM, Gross CA. 2004. Regulation of the Escherichia coli sigmadependent envelope stress response. Mol. Microbiol. 52:613-619.
9. McBroom AJ, Kuehn MJ. 2007. Release of outer membrane vesicles by Gram-negative bacteria is a novel envelope stress response. Mol. Microbiol. 63:545-558.
10. Choi DS, Kim DK, Choi SJ, Lee J, Choi JP, Rho S, Park SH, Kim YK, Hwang D, Gho YS. 2011. Proteomic analysis of outer membrane vesicles derived from Pseudomonas aeruginosa. Proteomics 11:3424-3429.
11. Kadurugamuwa JL, Beveridge TJ. 1995. Virulence factors are released from Pseudomonas aeruginosa in association with membrane vesicles during normal growth and exposure to gentamicin: a novel mechanism of enzyme secretion. J. Bacteriol. 177:3998-4008.
12. Montes LR, Ibarguren M, Goni FM, Stonehouse M, Vasil ML, Alonsoa A. 2007. Leakage-free membrane fusion induced by the hydrolytic activity of PlcHR(2), a novel phospholipase C/sphingomyelinase from Pseudomonas aeruginosa. Biochim. Biophys. Acta 1768:2365-2372.
13. Kohler T, Perron GG, Buckling A, van Delden C. 2010. Quorum sensing inhibition selects for virulence and cooperation in Pseudomonas aeruginosa. PLoS Pathog. 6:e1000883. doi:10.1371/journal.ppat.1000883.
14. Freudenberg MA, Tchaptchet S, Keck S, Fejer G, Galanos C. 2008. Lipopolysaccharide sensing an important factor in the innate immune response to Gram-negative bacterial infections: benefits and hazards of LPS hypersensitivity. Immunobiology 213:193-203.
15. Opal SM. 2007. The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis. Int. J. Med. Microbiol. 297:365-377.
16. Akira S, Takeda K. 2004. Toll-like receptor signaling. Nat. Rev. Immunol. 4:499-511.
17. Erridge C, Pridmore A, Eley A, Stewart J, Poxton IR. 2004. Lipopolysaccharides of Bacteroides fragilis, Chlamydia trachomatis and Pseudomonas aeruginosa signal via Toll-like receptor 2. J. Med. Microbiol. 53:735-740.
18. Bomberger JM, Ye S, MacEachran DP, Koeppen K, Barnaby RL, O'Toole GA, Stanton BA. 2011. A Pseudomonas aeruginosa toxin that hijacks the host ubiquitin proteolytic system. PLoS Pathog. 7:e1001325. doi:10.1371/journal.ppat.1001325.
19. MacEachran DP, Ye S, Bomberger JM, Hogan DA, Swiatecka-Urban A, Stanton BA, O'Toole GA. 2007. The Pseudomonas aeruginosa secreted protein PA2934 decreases apical membrane expression of the cystic fibrosis transmembrane conductance regulator. Infect. Immun. 75:3902-3912.
20. Ellis TN, Leiman SA, Kuehn MJ. 2010. Naturally produced outer membrane vesicles from Pseudomonas aeruginosa elicit a potent innate immune response via combined sensing of both lipopolysaccharide and protein components. Infect. Immun. 78:3822-3831.
21. Lee DH, Kim SH, Kang W, Choi YS, Lee SH, Lee SR, You S, Lee HK, Chang KT, Shin EC. 2011. Adjuvant effect of bacterial outer membrane vesicles with penta-acylated lipopolysaccharide on antigen-specific T cell priming. Vaccine 29:8293-8301.
22. Zughaier S, Steeghs L, van der Ley P, Stephens DS. 2007. TLR4-dependent adjuvant activity of Neisseria meningitidis lipid A. Vaccine 25:4401-4409.
23. Fransen F, Stenger RM, Poelen MC, van Dijken HH, Kuipers B, Boog CJ, van Putten JP, van Els CA, van der Ley P. 2010. Differential effect of TLR2 and TLR4 on the immune response after immunization with a vaccine against Neisseria meningitidis or Bordetella pertussis. PLoS One 5:e15692. doi:10.1371/journal.pone.0015692.
24. Gorringe AR, Halliwell D, Matheson M, Reddin K, Finney M, Hudson M. 2005. The development of a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Vaccine 23:2210-2213.
25. Mirlashari MR, Lyberg T. 2003. Expression and involvement of Toll-like receptors (TLR)2, TLR4, and CD14 in monocyte TNF-alpha production induced by lipopolysaccharides from Neisseria meningitides. Med. Sci. Monit. 9:316-324.
26. Morley SL, Pollard AJ. 2001. Vaccine prevention of meningococcal disease, coming soon? Vaccine 20:666-687.
27. Oliver KJ, Reddin KM, Bracegirdle P, Hudson MJ, Borrow R, Gorringe AR. 2002. Neisseria lactamica protects against experimental meningococcal infection. Infect. Immun. 70:3621-3626.
28. Gorringe AR, Taylor S, Brookes C, Matheson M, Finney M, Kerr M, Hudson M, Findlow J, Borrow R, Andrew N, Kafatos G, Evans CM, Read RC. 2009. Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Clin. Vaccine Immunol. 8:1113-1120.
29. Bauman SJ, Kuehn MJ. 2006. Purification of outer membrane vesicles from Pseudomonas aeruginosa and their activation of an IL-8 response. Microbes Infect. 8:2400-2408.
30. Abe K, Matsuki N. 2000. Measurement of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction activity and lactate dehydrogenase release using MTT. Neurosci. Res. 38:325-329.
31. Mullarkey M, Rose JR, Bristol J, Kawata T, Rossignol DP. 2003. Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther. 304:1093-1102.
32. Yuan K, Huang C, Fox J, Gaid M, Weaver A, Li G, Singh BB, Gao H, Wu M. 2011. Elevated inflammatory response in caveolin-1-deficient mice with Pseudomonas aeruginosa infection is mediated by STAT3 protein and nuclear factor B (NF-κB). J. Biol. Chem. 286:21814-21825.
33. Wu M, Hussain S, He HY, Pasula R, Smith PA, Martin WJ, II. 2001. Genetically engineered macrophages expressing IFN-γ restore alveolar immune function in SCID mice. Proc. Natl. Acad. Sci. U. S. A. 98:14589-14594.
34. PfafflMW. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e45. doi:10.1093/nar/29.9.e45.
35. Wu M, Huang H, Zhang W, Kannan S, Weaver A, Mckibben M, Herington D, Zeng H, Gao H. 2011. Host DNA repair proteins in response to Pseudomonas aeruginosa in lung epithelial cells and in mice. Infect. Immun. 79:75-87.
36. He Y, Xu Y, Kobune Y, Wu M, Kelley MR, Martin WJ, II. 2002. Escherichia coli Fpg and human Ogg1 reduce DNA damage and cytotoxicity by BCNU in human lung cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 282:50-55.
37. Renelli M, Matias V, Lo RY, Beveridge TJ. 2004. DNA-containing membrane vesicles of Pseudomonas aeruginosa PAO1 and their genetic transformation potential. Microbiology 150:2161-2169.
38. Ahmad-Nejad P, Häcker H, Rutz M, Bauer S, Vabulas RM, Wagner H. 2002. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 32:1958-1968.
39. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408:740-745.
40. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Golenbock DT. 2004. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 5:190-198.
41. Le Berre R, Nguyen S, Nowak E, Kipnis E, Pierre M, Ader F, Courcol R, Guery BP, Faure K. 2008. Quorum-sensing activity and related virulence factor expression in clinically pathogenic isolates of Pseudomonas aeruginosa. Clin. Microbiol. Infect. 14:337-343.
42. Naenna P, Noisumdaeng P, Pongpech P, Tribuddharat C. 2010. Detection of outer membrane porin protein, an imipenem influx channel, in Pseudomonas aeruginosa clinical isolates. Asian J. Trop. Med. Public Health 41:614-624.
43. Sanbongi Y, Shimizu A, Suzuki T, Nagaso H, Ida T, Maebashi K, Gotoh N. 2009. Classification of OprD sequence and correlation with antimicrobial activity of carbapenem agents in Pseudomonas aeruginosa clinical isolates collected in Japan. Microbiol. Immunol. 53:361-367.
44. Deng X, Weerapana E, Ulanovskaya O, Sun F, Liang H, Ji Q, Ye Y, Fu Y, Zhou L, Li J, Zhang H, Wang C, Alvarez S, Hicks LM, Lan L, Wu M, Cravatt BF, He C. 2013. Proteome-wide quantification and characterization of oxidation-sensitive cysteines in pathogenic bacteria. Cell Host Microbe 13:358-370.
45. Skerrett SJ, Wilson CB, Liggitt HD, Hajjar AM. 2007. Redundant Toll-like receptor signaling in the pulmonary host response to Pseudomonas aeruginosa. Am. J. Physiol. Lung Cell. Mol. Physiol. 292:312-322.
46. Schurr JR, Young E, Byrne P, Steele C, Shellito JE, Kolls JK. 2005. Central role of Toll-like receptor 4 signaling and host defense in experimental pneumonia caused by Gram-negative bacteria. Infect. Immun. 73:532-545.
47. Ramphal R, Balloy V, Huerre M, Si-Tahar M, Chignard M. 2005. TLRs 2 and 4 are not involved in hypersusceptibility to acute Pseudomonas aeruginosa lung infections. J. Immunol. 175:3927-3934.
48. Alaniz RC, Deatherage BL, Lara JC, Cookson BT. 2007. Membrane vesicles are immunogenic facsimiles of Salmonella typhimurium that potently activate dendritic cells, prime B- and T-cell responses, and stimulate protective immunity in vivo. J. Immunol. 179:7692-7701.
49. Ismail S, Hampton MB, Keenan JI. 2003. Helicobacter pylori outer membrane vesicles modulate proliferation and interleukin-8 production by gastric epithelial cells. Infect. Immun. 71:5670-5675.
50. Kannan S, Knittel J, Mullegama S, Gao GF, Wu M. 2006. Src tyrosine kinase Lyn plays a role in Pseudomonas aeruginosa infection of respiratory epithelium cells. Eur. J. Immunol. 36:1739-1752.
51. Kamei A, Coutinho-Sledge YS, Goldberg JB, Priebe GP, Pier GB. 2011. Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection. Infect. Immun. 79:1289-1299.
52. Ramphal R, Balloy V, Jyot J, Verma A, Si-Tahar M, Chignard M. 2008. Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin. J. Immunol. 181:586-592.
53. Talati AJ, Kim HJ, Kim YI, Yi AK, English BK. 2008. Role of bacterial DNA in macrophage activation by group B streptococci. Microbes Infect. 10:1106-1113.